← 返回

CAR-T 细胞中 TNFRSF 共刺激结构域的应用以实现最佳功能活性

英文原题:The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.

查看英文原题

The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.

PubMed 2022/01/08(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤坏死因子受体超家族(TNFRSF)是一个庞大且重要的免疫调节家族,为许多(即使不是全部)免疫效应细胞提供关键的共刺激信号。每个共刺激TNFRSF成员都具有独特的表达谱,并在免疫反应的不同阶段对不同类型细胞产生独特的功能影响。相应地,利用TNFRSF介导的信号通路进行癌症免疫治疗一直是一个主要的研究领域,多种利用TNFRSF的治疗性抗癌方法如4-1BB和CD27激动性抗体正在(临床前)临床评估中。TNFRSF信号的进一步应用是将TNFRSF的细胞内共刺激结构域整合到所谓的嵌合抗原受体(CAR)构建体中用于CAR-T 细胞治疗,其中最突出的例子是临床获批产品Kymriah中所包含的4-1BB共刺激结构域。事实上,CAR-T 细胞功能可以明显受到TNFRSF成员独特共刺激特征的影响。

在此,我们综述了一组精选的TNFRSF成员(4-1BB、OX40、CD27、CD40、HVEM和GITR),这些成员作为CAR-T 细胞治疗中的共刺激结构域已获得广泛关注,并阐述了每个成员赋予CAR-T 细胞的独特特征。

展开英文摘要原文

The Tumor Necrosis Factor Receptor Superfamily (TNFRSF) is a large and important immunoregulatory family that provides crucial co-stimulatory signals to many if not all immune effector cells. Each co-stimulatory TNFRSF member has a distinct expression profile and a unique functional impact on various types of cells and at different stages of the immune response. Correspondingly, exploiting TNFRSF-mediated signaling for cancer immunotherapy has been a major field of interest, with various therapeutic TNFRSF-exploiting anti-cancer approaches such as 4-1BB and CD27 agonistic antibodies being evaluated (pre)clinically.

A further application of TNFRSF signaling is the incorporation of the intracellular co-stimulatory domain of a TNFRSF into so-called Chimeric Antigen Receptor (CAR) constructs for CAR-T cell therapy, the most prominent example of which is the 4-1BB co-stimulatory domain included in the clinically approved product Kymriah. In fact, CAR-T cell function can be clearly influenced by the unique co-stimulatory features of members of the TNFRSF.

Here, we review a select group of TNFRSF members (4-1BB, OX40, CD27, CD40, HVEM, and GITR) that have gained prominence as co-stimulatory domains in CAR-T cell therapy and illustrate the unique features that each confers to CAR-T cells.

论文信息

作者
He Y、Vlaming M、van Meerten T、Bremer E
第一作者单位
Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.China
通讯作者单位
Department of Hematology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.Netherlands
文献类型
综述
期刊
Cancers2022 Jan 8
原文标识
PubMed 35053463 · DOI 10.3390/cancers14020299